PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 71 filers reported holding PUMA BIOTECHNOLOGY INC in Q3 2023. The put-call ratio across all filers is 0.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $1,725,000 | -65.3% | 29,161 | -60.1% | 0.01% | -67.6% |
| Q1 2018 | $4,968,000 | +94.8% | 73,003 | +183.0% | 0.03% | +70.0% |
| Q4 2017 | $2,550,000 | -61.3% | 25,800 | -53.1% | 0.02% | -52.4% |
| Q3 2017 | $6,593,000 | -19.7% | 55,058 | -41.4% | 0.04% | -19.2% |
| Q2 2017 | $8,215,000 | +41.0% | 93,993 | -40.0% | 0.05% | +10.6% |
| Q1 2017 | $5,825,000 | +148.4% | 156,597 | +105.0% | 0.05% | +104.3% |
| Q4 2016 | $2,345,000 | +92.8% | 76,400 | +321.2% | 0.02% | +109.1% |
| Q3 2016 | $1,216,000 | -60.1% | 18,140 | -30.4% | 0.01% | -64.5% |
| Q2 2015 | $3,045,000 | +265.1% | 26,079 | +638.6% | 0.03% | +287.5% |
| Q1 2015 | $834,000 | -28.7% | 3,531 | -27.9% | 0.01% | -55.6% |
| Q3 2014 | $1,169,000 | +328.2% | 4,900 | +18.4% | 0.02% | +200.0% |
| Q2 2014 | $273,000 | -92.8% | 4,140 | -88.6% | 0.01% | -91.3% |
| Q1 2014 | $3,770,000 | +328.4% | 36,200 | +325.9% | 0.07% | +305.9% |
| Q4 2013 | $880,000 | – | 8,500 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| EcoR1 Capital, LLC | 2,536,156 | $21,405,000 | 2.24% |
| Palo Alto Investors LP | 1,396,163 | $11,784,000 | 0.99% |
| Camber Capital Management LP | 1,950,000 | $16,458,000 | 0.98% |
| TANG CAPITAL MANAGEMENT LLC | 800,000 | $6,752,000 | 0.95% |
| Capital Impact Advisors, LLC | 147,303 | $1,243,000 | 0.52% |
| Sofinnova Investments, Inc. | 638,026 | $5,385,000 | 0.50% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 963,212 | $8,130,000 | 0.26% |
| RICE HALL JAMES & ASSOCIATES, LLC | 466,482 | $3,937,000 | 0.22% |
| PDT Partners, LLC | 204,238 | $1,724,000 | 0.14% |
| Eversept Partners, LP | 58,251 | $491,638 | 0.12% |